ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Received FDA IND clearance for ALX2004, a potential first-in-class EGFR ADC
- Strong cash position of $107.0M with runway extended into Q4 2026
- Reduced net loss to $30.8M from $35.6M year-over-year
- Promising results in B-NHL trial with 83% complete response rate vs 34% historical rate
- R&D expenses decreased by $7.8M compared to prior year
- Failed to meet primary endpoints in ASPEN-03 and ASPEN-04 Phase 2 trials
- Cannot pursue accelerated approval pathway for gastric cancer due to FDA feedback
- Discontinued evorpacept evaluation in urothelial cancer due to insufficient efficacy
- G&A expenses increased by $1.9M compared to prior year
Insights
ALX Oncology narrows pipeline focus to antibody combinations while advancing new ADC; gastric cancer approval path closed but runway extended.
ALX Oncology's Q1 report reveals significant strategic realignment aimed at extending their
The FDA clearance for ALX2004, their proprietary EGFR-targeted ADC, represents a crucial pipeline diversification beyond evorpacept. This potentially first-in-class asset is slated to enter clinical trials mid-2025, with initial safety data expected in 1H 2026.
However, regulatory setbacks have narrowed their path forward. The FDA determined that ASPEN-06 data wasn't eligible for accelerated approval in gastric cancer due to ENHERTU's establishment as standard-of-care, effectively closing a potential near-term approval route. Similarly, the company discontinued evaluation of evorpacept with PADCEV in urothelial cancer after final data analysis showed inadequate efficacy improvement.
Their R&D expenses decreased
The most compelling data supporting their antibody combination strategy comes from the Phase 1 NHL trial, where evorpacept plus R2 generated complete responses in
- Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025
- IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20
- Company will not pursue U.S. registrational path in gastric cancer following receipt of FDA feedback that accelerated approval pathway is not feasible based on ASPEN-06 due to standard-of-care evolving to ENHERTU®
- Data milestones expected across Company’s three clinical programs in 2026
- Cash runway has been extended into Q4 2026
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.
“In the first quarter of the year, we focused our development strategy for evorpacept on the anti-cancer antibody combinations, as we now have proof-of-concept for this mechanism in gastric cancer, breast cancer and NHL,” said Jason Lettmann, Chief Executive Officer of ALX Oncology. “In addition to the evorpacept program, we diversified our pipeline by moving our in-house ADC candidate, ALX2004, through IND clearance and look forward to beginning clinical trial enrollment by mid-year for this potentially first- and best-in-class EGFR ADC. We also made the difficult but critical decision to streamline the company and, by doing so, extended cash runway into Q4 2026. We are now hyper-focused on pursuing the validated mechanism of action for evorpacept in combination with anti-cancer antibodies and delivering data in breast cancer in combination with HERCEPTIN®, in colorectal cancer in combination with ERBITUX®, as well as from ALX2004, in 2026.”
ALX Oncology Q1 2025 Highlights and Recent Developments
- Received Investigational New Drug (IND) clearance for ALX2004 from the U.S. Food and Drug Administration (FDA). ALX2004 is a potential best- and first-in-class ADC for the treatment of epidermal growth factor receptor (EGFR)-expressing solid tumors that was fully designed and developed in-house by ALX Oncology scientists utilizing the Company’s proprietary linker-payload platform. Phase 1 clinical trials of ALX2004 are expected to initiate in mid-2025, with initial safety data available in 1H 2026. ALX Oncology will host a webcast highlighting the research program, clinical progress and novel mechanism of action for ALX2004 on May 20, 2025.
- Continued progress with the Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC clinical studies evaluating evorpacept in combination with anti-cancer antibodies and chemotherapy in breast and colorectal cancers based on strong supporting data that, when combined with an anti-cancer antibody, evorpacept generates durable responses and a consistent safety profile. First patient dosing for both trials is anticipated mid-year 2025.
- The randomized Phase 2 ASPEN-Breast clinical trial will evaluate evorpacept with HERCEPTIN® (trastuzumab) and single-agent chemotherapy in patients with HER2-positive metastatic breast cancer after prior treatment with ENHERTU® (fam-trastuzumab deruxtecan-nxki).
- The Phase 1 ASPEN-CRC clinical trial will evaluate evorpacept with ERBITUX® (cetuximab) and FOLFIRI in patients with second-line metastatic colorectal cancer.
- Announced encouraging final results from the Phase 1 trial evaluating evorpacept with standard-of-care RITUXAN® (rituximab) and lenalidomide (R2) treatment in patients with B-cell non-Hodgkin Lymphoma (B-NHL) presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The trial was conducted by Paolo Strati, M.D., Associate Professor of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center, and colleagues at MD Anderson.
- As previously published, the combination of evorpacept plus R2 was well tolerated and demonstrated promising anti-tumor activity, generating complete responses (CR) in
83% of patients with indolent relapsed or refractory B-NHL comparing favorably to the34% historical CR rate with R2 alone. - The Phase 2 portion of the trial in patients with previously untreated indolent NHL is ongoing and has completed enrollment.
- As previously published, the combination of evorpacept plus R2 was well tolerated and demonstrated promising anti-tumor activity, generating complete responses (CR) in
- Reported topline results from the ASPEN-03 and ASPEN-04 Phase 2 trials evaluating evorpacept with a checkpoint inhibitor, which did not meet their primary endpoints. In the trials, efficacy data did not support advancing evorpacept in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational study. The combination of evorpacept and pembrolizumab with or without chemotherapy in ASPEN-03 and ASPEN-04 demonstrated a manageable safety profile and was consistent with what has been previously reported for pembrolizumab and chemotherapy in this setting.
- Received guidance from the U.S. FDA that the ASPEN-06 Phase 2 trial data evaluating evorpacept in combination with trastuzumab, ramucirumab and paclitaxel was not eligible for submission for accelerated approval given the availability of ENHERTU®. A Phase 3 versus ENHERTU® trial would be needed to pursue a regulatory approval of evorpacept in the second-line setting for HER2-positive gastric and gastroesophageal cancers. Given the Company’s disciplined focus and the allocation of its resources, ALX Oncology will not pursue a U.S. registrational path with a Phase 3 trial in gastric cancer and will consider exploring development partnerships to advance this program in gastric cancer.
- The Company made the decision to discontinue its evaluation of evorpacept in combination with PADCEV® (enfortumab vedotin-ejfv) in urothelial cancer based on the final data analysis showing that, in the ASPEN-07 trial, the addition of evorpacept to treatment with PADCEV® did not meet the bar for improved efficacy. Aligned to these data and consistent with recent guidance, ALX Oncology maintains its focus on continuing to progress its trials of evorpacept with anti-cancer antibodies, where there is demonstrated proof-of-concept across multiple clinical settings.
- Through previously announced strategic reprioritization efforts, the Company extended its cash runway into Q4 2026. Data milestones that are expected across the three studies evaluating evorpacept and ALX2004 are included in cash runway.
Upcoming Clinical Milestones
- Breast Cancer: Patient dosing anticipated to initiate for ASPEN-BREAST Phase 2 clinical trial in mid-year 2025. Interim results from this trial are anticipated in 2H 2026.
- Colorectal Cancer: Patient dosing anticipated to initiate for ASPEN-CRC Phase 1b clinical trial in mid-year 2025. Safety and early efficacy data are anticipated in 1H 2026.
- ALX2004: Patient dosing anticipated to initiate in mid-2025, following IND clearance from the FDA in April 2025. Safety data are anticipated in 1H 2026.
- Breast Cancer: Topline results from Phase 1b I-SPY clinical trial of evorpacept with ENHERTU® are anticipated in 2H 2025.
First Quarter 2025 Financial Results
- Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of March 31, 2025, were
$107.0 million . The Company believes its cash, cash equivalents and investments are sufficient to fund planned operations into Q4 of 2026. - Research and Development (“R&D”) Expenses: R&D expenses consist primarily of preclinical, clinical and development costs related to the development of the Company’s current lead product candidate, evorpacept, and R&D personnel-related expenses including stock-based compensation. R&D expenses for the three months ended March 31, 2025, were
$23.9 million compared to$31.7 million for the prior-year period or a decrease of$7.8 million . This decrease was primarily attributable to a decrease of$7.0 million in clinical and development costs primarily due to less manufacturing of clinical trial materials to support active clinical trials for our lead product candidate, evorpacept, and a decrease in stock-based compensation expense slightly offset by increased personnel and related costs. - General and Administrative (“G&A”) Expenses: G&A expenses consist primarily of administrative personnel-related expenses, including stock-based compensation and other costs such as legal and other professional fees, patent filing and maintenance fees, and insurance. G&A expenses for the three months ended March 31, 2025, were
$7.9 million compared to$6.0 million for the prior year period or an increase of$1.9 million . This increase was primarily attributable to an increase in personnel and related costs. - Net loss: GAAP net loss was (
$30.8) million for the three months ended March 31, 2025, or ($0.58) per basic and diluted share, as compared to a GAAP net loss of ($35.6) million for the three months ended March 31, 2024, or ($0.71) per basic and diluted share. The lower net loss is primarily attributed to lower R&D expenses. Non-GAAP net loss was ($25.5) million for the three months ended March 31, 2025, as compared to a non-GAAP net loss of ($28.5) million for the three months ended March 31, 2024. A reconciliation of GAAP to non-GAAP financial results can be found at the end of this news release.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objectives of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (“SEC”), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
| ALX ONCOLOGY HOLDINGS INC. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts) | ||||||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2025 | 2024 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 23,888 | $ | 31,717 | ||||
| General and administrative | 7,932 | 6,045 | ||||||
| Total operating expenses | 31,820 | 37,762 | ||||||
| Loss from operations | (31,820 | ) | (37,762 | ) | ||||
| Interest income | 1,483 | 2,622 | ||||||
| Interest expense | (406 | ) | (427 | ) | ||||
| Other (expense) income, net | (11 | ) | (14 | ) | ||||
| Net loss | $ | (30,754 | ) | $ | (35,581 | ) | ||
| Net loss per share, basic and diluted | $ | (0.58 | ) | $ | (0.71 | ) | ||
| Weighted-average shares of common stock used to compute net loss per shares, basic and diluted | 53,359,338 | 50,120,758 | ||||||
| Condensed Consolidated Balance Sheet Data (unaudited) (in thousands) | ||||||||
| March 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Cash, cash equivalents and investments | $ | 106,992 | $ | 131,281 | ||||
| Total assets | $ | 120,900 | $ | 147,775 | ||||
| Total liabilities | $ | 32,605 | $ | 34,157 | ||||
| Accumulated deficit | $ | (651,876 | ) | $ | (621,122 | ) | ||
| Total stockholders’ equity | $ | 88,295 | $ | 113,618 | ||||
| GAAP to Non-GAAP Reconciliation (unaudited) (in thousands) | ||||||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2025 | 2024 | |||||||
| GAAP net loss, as reported | $ | (30,754 | ) | $ | (35,581 | ) | ||
| Adjustments: | ||||||||
| Stock-based compensation expense | 5,216 | 7,031 | ||||||
| Accretion of term loan discount and issuance costs | 67 | 64 | ||||||
| Total adjustments | 5,283 | 7,095 | ||||||
| Non-GAAP net loss | $ | (25,471 | ) | $ | (28,486 | ) | ||
Use of Non-GAAP Financial Measures
We supplement our consolidated financial statements presented on a GAAP basis by providing additional measures which may be considered “non-GAAP” financial measures under applicable SEC rules. We believe that the disclosure of these non-GAAP financial measures provides our investors with additional information that reflects the amounts and financial basis upon which our management assesses and operates our business. These non-GAAP financial measures are not in accordance with generally accepted accounting principles and should not be viewed in isolation or as a substitute for reported, or GAAP, net loss, and are not a substitute for, or superior to, measures of financial performance performed in conformity with GAAP.
“Non-GAAP net loss” is not based on any standardized methodology prescribed by GAAP and represents GAAP net loss adjusted to exclude stock-based compensation expense and accretion of term loan discount and issuance costs. Non-GAAP financial measures used by ALX Oncology may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Audra Friis, Sam Brown LLC
audrafriis@sambrown.com
(917) 519-9577
FAQ
What is the current cash position of ALX Oncology (ALXO) as of Q1 2025?
Why did ALXO abandon its gastric cancer program?
What are the key upcoming milestones for ALXO in 2025-2026?
How did ALX Oncology's Q1 2025 financial results compare to Q1 2024?
What is ALX2004 and what is its development status?
